Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains;2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium;3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research;4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done;and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a "One Harvard" community and culture committed to improving health.

Public Health Relevance

The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Mentored Career Development Award (KL2)
Project #
1KL2TR001100-01
Application #
8721083
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S1))
Program Officer
Talbot, Bernard
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2013-09-26
Budget End
2014-04-30
Support Year
1
Fiscal Year
2013
Total Cost
$1,131,170
Indirect Cost
Name
Harvard University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Christensen, K D; Vassy, J L; Jamal, L et al. (2016) Are physicians prepared for whole genome sequencing? a qualitative analysis. Clin Genet 89:228-34
Kryukov, Gregory V; Wilson, Frederick H; Ruth, Jason R et al. (2016) MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351:1214-8
Chahal, Harpreet S; Mostofsky, Elizabeth; Mittleman, Murray A et al. (2016) Aerobic Fitness and Risk of Ventricular Arrhythmia Following Physical Exertion. Can J Cardiol 32:533-8
Wang, Weike; Yang, Meng; Kenfield, Stacey A et al. (2016) Nut consumption and prostate cancer risk and mortality. Br J Cancer 115:371-4
Giannakis, Marios; Mu, Xinmeng Jasmine; Shukla, Sachet A et al. (2016) Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep :
Wilker, Elissa H; Martinez-Ramirez, Sergi; Kloog, Itai et al. (2016) Fine Particulate Matter, Residential Proximity to Major Roads, and Markers of Small Vessel Disease in a Memory Study Population. J Alzheimers Dis 53:1315-23
Jung, Hee-Won; Jang, Il-Young; Lee, Young Soo et al. (2016) Prevalence of Frailty and Aging-Related Health Conditions in Older Koreans in Rural Communities: a Cross-Sectional Analysis of the Aging Study of Pyeongchang Rural Area. J Korean Med Sci 31:345-52
Chan, Brian T; Tsai, Alexander C (2016) Reply to "Trends in responses to DHS questions should not be interpreted as reflecting an increase in 'anticipated stigma' in Africa". J Acquir Immune Defic Syndr :
Moghari, Mehdi H; Geva, Tal; Powell, Andrew J (2016) Prospective heart tracking for whole-heart magnetic resonance angiography. Magn Reson Med :
Chikata, Yuichi; Iwata, Hiroshi; Osborn, Eric A et al. (2016) Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3). Int J Cardiol 212:148-50

Showing the most recent 10 out of 67 publications